INTERVIEW: Yabao Sees Niche As Domestic Asset Appetite Swells
This article was originally published in PharmAsia News
Executive Summary
Bagging four alliance deals in one year including one with Lilly for diabetes, Yabao Pharma sees a wide opening for international collaboration on early stage drug development in China, driven by rising domestic demand for innovative drug candidates, says president of R&D Peng Wang in an exclusive interview.